Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.51 |
| ▸ | HTR2C | P28335 | 6/20 | 0.51 |
| ▸ | PNMT | P11086 | 2/20 | 0.44 |
| ▸ | CD44 | P16070 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5317898 | 0.98 | HTR2A (0.50) | HTR2AHTR2CPNMTCD44MAOB | |
| Phosphoric Acid SCHEMBL174685 | 0.91 | HTR2A (0.44) | HTR2AHTR2CPNMTCD44MAOB | |
| SCHEMBL174465 | 0.89 | HTR2C (0.43) | HTR2AHTR2CPNMTCD44MAOB | |
| Glycolic Acid SCHEMBL174591 | 0.87 | HTR2A (0.41) | HTR2AHTR2CPNMTCD44MAOB | |
| Malonic Acid SCHEMBL174326 | 0.87 | HTR2A (0.41) | HTR2AHTR2CPNMTCD44MAOB | |
| Succinic Acid SCHEMBL175159 | 0.87 | HTR2A (0.41) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| Adipic Acid SCHEMBL173981 | 0.84 | L3MBTL1 (0.41) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL9058489 | 0.83 | HTR2A (0.62) | HTR2AHTR2CPNMTCD44MAOB | |
| Alpha-Ketoglutaric Acid SCHEMBL174485 | 0.81 | HTR2A (0.37) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL6298572 | 0.81 | HTR2A (0.73) | HTR2AHTR2CPNMTSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106478506-B | The preparation method of half light green Ka Selin hydrochloride | 山东科兴生物制品有限公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-105693610-B | The preparation method of lorcaserin intermediate | 国药集团宜宾制药有限责任公司 | 2019-01-11 | — | — | CN | disclosed |
| US-9770455-B2 | Administration of an anti-obesity compound to individuals with renal impairment | ARENA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170216307-A1 | ADMINISTRATION OF AN ANTI-OBESITY COMPOUND TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| CN-106432080-A | Method for resolution of R/S-lorcaserin by high performance liquid chromatography method | 南京医科大学 | 2017-02-22 | — | — | CN | disclosed |
| US-20150196567-A1 | ADMINISTRATION OF AN ANTI-OBESITY COMPOUND TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. | 2015-07-16 | — | — | US | disclosed |
| EP-2611782-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611427-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT& xA; | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2443080-A2 | PROCESS FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2012030953-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030927-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030938-A1 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2010148207-A2 | PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216307-A1 | ADMINISTRATION OF AN ANTI-OBESITY COMPOUND TO INDIVIDUALS WITH RENAL IMPAIRMENT | REN, GLS, GPR119 | HTR2A 235/4885HTR2C 155/4885PNMT 95/4885 |
| US-20150196567-A1 | ADMINISTRATION OF AN ANTI-OBESITY COMPOUND TO INDIVIDUALS WITH RENAL IMPAIRMENT | REN, GLS, GPR119 | HTR2A 235/4885HTR2C 155/4885PNMT 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.